Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Migraine Drug Atogepant Delivers Good News When Allergan Needs It Most

Executive Summary

Oral CGRP inhibitor atogepant delivers strong Phase IIb/III results in episodic migraine prevention less than a week after activist investors went public with their push for a management shakeup to reverse Allergan's falling stock price.

Advertisement

Related Content

Novartis To Ape Aimovig's US Market Strategy In The EU As CHMP Gives Market Go-Ahead
Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price
Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?
Teva Pushes CGRP Timeline Back To End Of 2018
Allergan's Ubrogepant Succeeds In Second Acute Migraine Phase III Study
Allergan Touts Ubrogepant Phase III Success, But Liver Tox Concerns Overhang
Response Rates Rule In CGRP Inhibitor Migraine Studies
Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race
Allergan migraine portfolio grows with Merck CGRP antagonists
Telcagepant failure is a headache for Merck (and perhaps Pfizer) but a break for others

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123238

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel